Compare Gilead Sciences, Inc. (GILD) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Target Corporation — how do they compare? Gilead Sciences, Inc. trades at $136 (market cap $163.51B), while Target Corporation trades at $140.13 (market cap $62.81B). The key difference: Gilead Sciences, Inc. is far larger — about 2.6× Target Corporation's market cap, and Target Corporation pays the higher dividend (3.36%). Which is the better fit depends on your goals.
| GILD | TGT | |
|---|---|---|
Market Cap | $163.51B | $62.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $155.80 | $141.19 |
52-Week Low | $108.22 | $83.68 |
Enterprise Value | $178.05B | $78.11B |
Dividend Yield | 2.49% | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Target (TGT) trades at $140.69, up 5.02% today, with strong technical momentum indicated by bullish moving averages. Recent earnings beats and a 3.24% net income margin highlight operational resilience, while a P/E of 18.27 and P/S of 0.59 suggest reasonable valuation. Positive news flow notes improving traffic trends from merchandising initiatives, supporting near-term optimism.
The outlook remains balanced with potential upside from execution on merchandising resets and consistent dividend payments, but risks include competitive pressures and margin volatility. Analyst consensus is mixed with a $137 price target slightly below current levels, indicating cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
